Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review
IET Nanobiotechnology · 2023-05 · 17 (3) · 154-170
DOI: 10.1049/nbt2.12127 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift IET Nanobiotechnology, online erschienen am 22.03.2023. Verfasst von Cyrus Jalili und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Biology Research Center, Research Institute for Health Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran. Hauptthemen laut MEDLINE: Alzheimer Disease, Nanoparticles. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 209 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is one of the chief neurological difficulties in the aged population, identified through dementia, memory disturbance, and reduced cognitive abilities. β ‐amyloid (Aβ) plaques aggregations, generation of reactive oxygen species, and mitochondrial dysfunction are among the major signs of AD. Regarding the urgent need for the development of novel treatments for neurodegenerative diseases, researchers have recently perused the function of natural phytobioactive combinations, such as resveratrol (RES), in vivo and in vitro (animal models of AD). Investigations have shown the neuroprotective action of RES. This compound can be encapsulated by several methods (e.g. polymeric nanoparticles (NPs), solid lipid nanoparticles, Micelles, and liposomes). This antioxidant compound, however, barely crosses the blood–brain barrier (BBB), thereby limiting its bioavailability and stability at the target sites in the brain. Thanks to nanotechnology, the efficiency of AD therapy can be improved by encapsulating the drugs in a NP with a controlled size (1–100 nm). This article addressed the use of RES, as a Phytobioactive compound, to decrease the oxidative stress. Encapsulation of this compound in the form of nanocarriers to treat neurological diseases to improve BBB crossing is also discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Biology Research Center, Research Institute for Health Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Regenerative Medicine Research Center, Research Institute for Health Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Department of Anatomical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
- Faculty, Anatomy Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
ORCID-Profile: Seyran Kakebaraei
Zitieren
APA
Jalili, C., Kiani, A., Gholami, M., Bahrehmand, F., Fakhri, S., Kakehbaraei, S., & Kakebaraei, S. (2023). Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review. IET Nanobiotechnology, 17(3), 154-170. https://doi.org/10.1049/nbt2.12127
Vancouver
Jalili C, Kiani A, Gholami M, Bahrehmand F, Fakhri S, Kakehbaraei S, et al. Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review. IET Nanobiotechnology. 2023;17(3):154-170. doi:10.1049/nbt2.12127
BibTeX
@article{Jalili2023,
author = {Jalili, Cyrus and Kiani, Amir and Gholami, Mohammadreza and Bahrehmand, Fariborz and Fakhri, Sajad and Kakehbaraei, Somayeh and Kakebaraei, Seyran},
title = {Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review},
journal = {IET Nanobiotechnology},
year = {2023},
volume = {17},
number = {3},
pages = {154--170},
doi = {10.1049/nbt2.12127}
}
EUVIMED